Improved overall survival in melanoma with combined dabrafenib and trametinib.
about
Resistant mechanisms to BRAF inhibitors in melanomaRedox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and TherapyCancer pharmacogenomics, challenges in implementation, and patient-focused perspectivesThe evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinibState of the science on prevention and screening to reduce melanoma incidence and mortality: The time is nowDabrafenib: a new opportunity for the treatment of BRAF V600-positive melanomaClinical utility of nivolumab in the treatment of advanced melanomaRenal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International NetworkCombination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapyUpdates in Therapy for Advanced MelanomaMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyVemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic MelanomaNew therapeutic strategies for BRAF mutant colorectal cancersMedical management of malignant melanomaLong-term survival as a treatment benchmark in melanoma: latest results and clinical implicationsOther targeted drugs in melanomaTailoring the Treatment of Melanoma: Implications for Personalized MedicineTreatment Individualization in Colorectal CancerPembrolizumab: First in Class for Treatment of Metastatic MelanomaRecent advances in the treatment of melanoma with BRAF and MEK inhibitorsMore than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsThe influence of subclonal resistance mutations on targeted cancer therapyBRAF Mutation in Colorectal Cancer: An UpdateNew developments in the management of advanced melanoma - role of pembrolizumabTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatmentTrametinib: a MEK inhibitor for management of metastatic melanomaHistone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsCombination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done YetRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsA periodic table for cancerTargeting cancer with kinase inhibitorsCIViC databaseRAF inhibitors that evade paradoxical MAPK pathway activationPrimary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeBRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune ResponsesThe Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung CancerApproaches to modernize the combination drug development paradigm
P2860
Q26739717-D906175A-0E29-438B-975A-DEEE95991DA2Q26740191-DC3825D1-6F12-4FB4-824D-524635D4A7F4Q26741009-F14DCC94-D1E0-4212-AF1D-CB4FBA238F20Q26744335-B0792679-1E8B-46C8-8067-CE378C94787AQ26745557-0CD58DF0-C381-4BE5-A940-F70B7C1822CFQ26745933-B4AD5718-21FE-4048-87E1-1DC9E1095A27Q26751268-7A73415B-1B08-454D-8479-76637C2798B6Q26764883-D433C8E8-6171-41C2-AFFB-77B01C6CB3D3Q26769870-2328CE47-1FEB-42BC-A384-0ABEF5E6B7CCQ26771119-98F1F904-E576-4C24-8E93-9B72258DCFA6Q26771192-387B0629-2151-4190-92AB-79304BAEB07BQ26771941-185D5F26-A059-40B1-BB4A-7EBC1AA7F02DQ26772277-B098B0DB-2016-4735-8A15-03028C33965EQ26773302-A5F4F181-B582-49AE-B4E0-96B0F56BA55EQ26775546-30695A16-F3C2-41CD-9BC2-944CE8382AA4Q26775594-D7313739-2D61-4040-AAC7-50DEFDE33F60Q26775806-BA23486B-0224-4944-858A-A389C0AA6370Q26776215-2C610C53-E71D-4656-AB42-A4321E797556Q26777886-8A9A472C-35DA-4F8A-914C-CD29E839307DQ26778769-D915CE44-A27F-4D3D-9B20-E9C3F1F1DB46Q26781662-575706C8-2390-44DC-A92C-D6095F618CBEQ26781693-551D0F44-3850-461F-AE84-136B334819B9Q26781926-EAD7503A-EA29-4C4C-8137-EFAE6D23A788Q26781931-D67F7C7D-433B-498C-8CD3-345B1DC177E0Q26782222-03118915-1F76-49F1-89E0-804AA203CC36Q26782585-712FBFE6-9A04-4AF5-B4E2-DA315CFC0FACQ26782976-93077A7E-BC33-419B-91C5-D5F3A4F50524Q26783032-16313C41-9D88-4798-AD37-79975D6F77C3Q26795735-4D484148-2864-480D-B4CD-A7F36ECC872BQ26799864-62832FBF-D755-4612-865F-0F7A37206C18Q26851417-74109C7E-6EEB-4BB0-8F10-DC62C8F0B243Q26858878-BBAD58D1-1D00-4007-97F5-70DCF0D03876Q26865765-6B4124F4-D3BC-4692-84CA-03D243508DD9Q27612411-CD144D09-02F2-42B3-98BC-2273E13ADC77Q27702299-29327ABC-25E2-42FD-A349-D956DC2D09AEQ27853295-2B58CF46-A938-4113-A039-9662D43733F4Q27853371-5F479DCC-419A-4B0E-93E9-FDF7AD2406D8Q28067141-7153BE6A-2056-4084-9B2A-BFCC95D3D294Q28067196-4B6B1B3D-935E-4C09-B67D-AEB770BA4439Q28072074-C76CB2DD-27A2-414E-A5F5-FF6A66C3E460
P2860
Improved overall survival in melanoma with combined dabrafenib and trametinib.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Improved overall survival in melanoma with combined dabrafenib and trametinib.
@ast
Improved overall survival in melanoma with combined dabrafenib and trametinib.
@en
Improved overall survival in melanoma with combined dabrafenib and trametinib.
@nl
type
label
Improved overall survival in melanoma with combined dabrafenib and trametinib.
@ast
Improved overall survival in melanoma with combined dabrafenib and trametinib.
@en
Improved overall survival in melanoma with combined dabrafenib and trametinib.
@nl
prefLabel
Improved overall survival in melanoma with combined dabrafenib and trametinib.
@ast
Improved overall survival in melanoma with combined dabrafenib and trametinib.
@en
Improved overall survival in melanoma with combined dabrafenib and trametinib.
@nl
P2093
P50
P3181
P356
P1476
Improved overall survival in melanoma with combined dabrafenib and trametinib.
@en
P2093
Andrzej Mackiewicz
Anne-Marie Martin
Boguslawa Karaszewska
Daniil Stroiakovski
Florent Grange
Ivana Krajsova
Jacob Schachter
Jeff Legos
Laurent Mortier
Michael Lichinitser
P3181
P356
10.1056/NEJMOA1412690
P407
P50
P577
2015-01-01T00:00:00Z